<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04117087</url>
  </required_header>
  <id_info>
    <org_study_id>J1994</org_study_id>
    <secondary_id>IRB00210915</secondary_id>
    <nct_id>NCT04117087</nct_id>
  </id_info>
  <brief_title>Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer</brief_title>
  <official_title>Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 study for patients with resected PDAC and mismatch repair (MMR)-p colorectal cancer
      (CRC) to evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine (KRAS
      peptide vaccine) with poly-ICLC adjuvant in combination with nivolumab and ipilimumab after
      adjuvant standard of care treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2020</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing study drug-related toxicities</measure>
    <time_frame>4 years</time_frame>
    <description>Number of participants experiencing study drug-related adverse events Grade 3 or higher as defined by CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fold change in interferon-producing mutant-KRAS-specific CD8 and CD4 T cells at 16 weeks</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Evaluated by the fold change in interferon-producing mutant-KRAS-specific cluster of differentiation 8 (CD8) and cluster of differentiation 4 (CD4) T cells after vaccination at 16 weeks compare to pre-vaccination baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of months from the date of first treatment until first documented disease recurrence or death</measure>
    <time_frame>4 years</time_frame>
    <description>Number of months from the date of first treatment until first documented disease recurrence or death. This will be used to assess Disease-free Survival (DFS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change of interferon (IFN)-γ-producing mutant-KRAS-specific CD8 and CD4 T cells</measure>
    <time_frame>Baseline, 4 years</time_frame>
    <description>Percent change pre-vaccination baseline compared to end of study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>KRAS peptide vaccine, Nivolumab, and Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KRAS peptide vaccine</intervention_name>
    <description>KRAS peptide vaccine will be administered on days 1, 8, 15 and 22. Five boost vaccinations with will be administered at 8-9 week intervals (on weeks 13, 22, 31, 40, and 49).
Drug: 1.8 mg KRAS peptide vaccine + 0.3mg Poly-ICLC</description>
    <arm_group_label>KRAS peptide vaccine, Nivolumab, and Ipilimumab</arm_group_label>
    <other_name>Hiltonol® (Poly-ICLC)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab 360 mg will be administered as a 30 minute IV infusion (-10min/+15min) on Day 1 of each 21 day cycle.
Drug: 360 mg IV</description>
    <arm_group_label>KRAS peptide vaccine, Nivolumab, and Ipilimumab</arm_group_label>
    <other_name>OPDIVO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10min/+15min) on Day 1 of Cycles 1, 3, 5, 7, 9, 11, 13, 15 and 17 of the study or every 6 weeks for a total of a year.
Drug: 1mg/kg IV</description>
    <arm_group_label>KRAS peptide vaccine, Nivolumab, and Ipilimumab</arm_group_label>
    <other_name>YERVOY®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years.

          -  Have histologically or cytologically - proven cancer of the pancreas or microsatellite
             stable (MSS)-colon.

          -  Does not have measurable disease by imaging.

          -  Have sufficient archival tumor tissue for next-generation sequencing (NGS) and
             immune-phenotyping.

          -  Have one of the six KRAS mutations (KRASG12C, KRASG12V, KRASG12D, KRASG12A, KRASG13D
             or KRASG12R) in vaccine expressed in tumor.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Life expectancy of greater than 6 months.

          -  Patients must have adequate organ and marrow function defined by study-specified
             laboratory tests prior to initial study drug.

          -  Woman of childbearing potential must have a negative pregnancy test and follow
             contraceptive guidelines as defined per protocol.

          -  Men must use acceptable form of birth control while on study.

          -  Ability to understand and willingness to sign a written informed consent document.

          -  Last dose of adjuvant chemotherapy or radiation therapy administered within 6 months
             of screening tests.

        Exclusion Criteria

          -  If expected to require any other form of systemic or localized antineoplastic therapy
             while on study.

          -  Within 2 weeks prior to first dose of study drug.

               -  Any systemic or topical corticosteroids at immunosuppressive agents.

               -  Any palliative or adjuvant radiation or gamma knife radiosurgery.

               -  Any chemotherapy.

          -  Within 4 weeks prior to first dose of study drug.

               -  Any investigational cytotoxic drug.

               -  Any investigational device.

               -  Has received a live vaccine.

               -  Received any allergen hyposensitization therapy.

               -  Received any growth factors, e.g. granulocyte-colony stimulating factor (G-CSF),
                  granulocyte macrophage-colony stimulating factor (GM-CSF), erythropoietin.

               -  Any major surgery.

          -  Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1,
             anti-PD-L2, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4), etc.).

          -  Hypersensitivity reaction to any monoclonal antibody.

          -  Known history or evidence of brain metastases.

          -  Has active autoimmune disease that has required systemic treatment in the past 2
             years, or a documented history of clinically severe autoimmune disease, or a syndrome
             that requires systemic steroids or immunosuppressive agents.

          -  Known history or concurrent interstitial lung disease.

          -  Has a pulse oximetry &lt; 92% on room air.

          -  Requires the use of home oxygen.

          -  Infection with HIV or hepatitis B or C.

          -  Uncontrolled intercurrent illness including, but not limited to, uncontrolled
             infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia,
             metastatic cancer, or psychiatric illness/social situations that would limit
             compliance with study requirements.

          -  Has been diagnosed with another cancer or myeloproliferative disorder within the past
             5 year.

          -  Has a diagnosis of immunodeficiency.

          -  Presence of any tissue or organ allograft, regardless of need for immunosuppression,
             including corneal allograft. Patients with a history of allogeneic hematopoietic stem
             cell transplant will be excluded.

          -  Any other sound medical, psychiatric, and/or social reason as determined by the
             Investigator.

          -  Unwilling or unable to follow the study schedule for any reason.

          -  Are pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nilofer Azad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Medical Institution</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Sartorius-Mergenthaler, RN</last_name>
    <phone>410-614-3644</phone>
    <email>Sartosu@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ellen Lilly-Forman, RN</last_name>
    <phone>443-287-4961</phone>
    <email>lillyel@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Sartorius-Mergenthaler, RN</last_name>
      <phone>410-614-3644</phone>
      <email>Sartosu@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ellen Foreman-Lilly, RN</last_name>
      <phone>443-287-4961</phone>
      <email>lillyel@jhmi.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 3, 2019</study_first_submitted>
  <study_first_submitted_qc>October 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2019</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>KRAS Peptide Vaccine</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>Anti-PD-1</keyword>
  <keyword>Anti-CTLA-4</keyword>
  <keyword>Neoantigen Vaccines</keyword>
  <keyword>Cancer Vaccines</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Colon Cancer</keyword>
  <keyword>Pancreatic Ductal Adenocarcinoma (PDAC)</keyword>
  <keyword>Resected MMR-p Colorectal Cancer</keyword>
  <keyword>Resected MMR-p Pancreatic Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Poly ICLC</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

